India Pharma Outlook Team | Friday, 23 October 2026
AbbVie’s lutikizumab trial has shown significant improvements in hidradenitis suppurativa (HS), a chronic inflammatory skin disease characterized by painful lumps and abscesses.
The Phase 3 INTREPID study met its primary endpoint at Week 16, but its performance against placebo raises questions over how well it can stand out in an increasingly crowded market
AbbVie is also preparing to investigate lutikizumab alongside ABBV-295, an experimental long-acting amylin analogue being developed for weight management.
The strategy could broaden the company’s approach to HS by examining inflammatory pathways alongside obesity disease burden, although the proposed combination remains investigational.
The INTREPID study evaluated lutikizumab in approximately 1,400 adults and adolescents with moderate to severe HS.
The investigational drug targets interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), inflammatory signaling molecules associated with HS lesions.
At Week 16, the primary endpoint, known as HiSCR75, was achieved by:
HiSCR75 requires at least a 75 percent reduction in abscesses and inflammatory nodules without an increase in abscesses or draining fistulas.
The results were statistically significant; however, the difference of 8 percentage points between treatment and placebo raises questions about the drug’s competitive prospects.
Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma
Beyond lesion counts, the AbbVie lutikizumab trial reported improvements in outcomes that affect patients’ daily lives.
Key findings included:
Kori Wallace, AbbVie’s vice president and global head of immunology clinical development, highlighted the importance of evaluating both physician-assessed disease response and patient-reported outcomes, including pain and flare frequency.
AbbVie plans to evaluate lutikizumab alongside ABBV-295; the program may also investigate combinations involving ABBV-701, an experimental anti-TL1A antibody.
The rationale is to examine multiple disease pathways rather than relying exclusively on one inflammatory target. Obesity can worsen HS for some patients, making the interaction between metabolic health and inflammation relevant to treatment research.
The proposed combination is not an established therapy, and the trial announcement does not demonstrate that adding ABBV-295 will improve HS outcomes.
AbbVie expects additional INTREPID data, including results from a 36-week blinded extension, in 2027. The company intends to use the findings to support potential regulatory review in the second half of 2027.
For now, the AbbVie lutikizumab trial provides evidence of clinical activity but leaves important questions about comparative efficacy, durability and the value of combination treatment.
These findings highlight evolving treatment approaches for chronic inflammatory diseases and the growing role of innovative drug development strategies in addressing unmet medical needs.
.jpg)
